CAMBRIDGE, Mass., April 10, 2025 /PRNewswire/ -- Pykus Therapeutics, Inc. ("Pykus" or the "Company") announced today that it has completed enrollment of its pilot study (PYK-2101-RD001) in Australia.
-- Results to date demonstrate rapid post-surgical visual recovery with no serious adverse events and meet or exceed FDA target rates for safety and effectiveness – -- Data presented today at ...
PYK-2101 is a novel, patented biodegradable hydrogel developed to dramatically improve the surgical recovery experience by directly sealing retinal breaks without obscuring vision, and eliminates the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results